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Metastasis is an important factor that regulates the prognosis of
patients with cancer. Tumour cells are scattered from the original
site, spreaded haematogenously and arrested at small vessels.
These cells must then adhere to the vascular endothelium, migrate
into the extracellular space and grow into secondary tumours.
Detection of these tumour cells circulating in peripheral blood
would be of interest to detect micrometastases at an early stage.
This might result in a more appropriate selection of patients for
adjuvant therapy.
A few tumour cells can be detected in a great excess of non-
malignant cells using nucleic acid amplification by means of the
polymerase chain reaction (PCR). In most cases, the detection
relies on the tissue specific expression of a gene (for recent
reviews see Denis et al, 1996; Pelkey et al, 1996; Verkaik et al,
1997; Bustin and Dorudi, 1998; Keilholz, 1998; Raj et al, 1998).
This gene has to be expressed in cancer cells but not in cells that
are normally present in blood. It can even be expressed in the
corresponding normal tissue if these normal cells do not circulate
in blood. Total RNA is extracted from whole blood or from
nucleated cells. Messenger RNAs are reverse transcribed and
the desired cDNA is amplified by PCR using specific oligo-
nucleotides.
In the past few years, several reports have illustrated the appli-
cation of this methodology to the detection of circulating
colorectal micrometastases. In most cases, cytokeratins gene
expression has been used to detect these epithelium-derived cells
(Burchill et al, 1995; Funaki et al, 1997; Le Maire et al, 1998;
Weitz et al, 1998; Wyld et al, 1998). Detections relying on the
expression of the carcinoembryonic antigen gene (Castells et al,
1998; Ko et al, 1998) and of apolipoprotein AI (Normanno et al,
1998) have also been recently documented. We previously
reported (Denis et al, 1997) the detection of tumour cell dissemi-
nation by reverse transcription polymerase chain reaction (RT-
PCR) in a pilot study of patients undergoing surgery for colorectal
cancer by using a combination of immunomagnetic separation and
cytokeratin 19-nested RT-PCR.
In all these reports, the phenotype of the cells is used. One
would like to assess the metastatic potential of these circulating
cells. This would help to distinguish between a harmless circu-
lating epithelial cell and one which would have given rise to a
metastasis. Therefore, there is need for more specific markers.
Colorectal tumorigenesis is a complex multistep process in
which genetic and epigenetic alterations accumulate to bring about
the neoplastic phenotype (Vogelstein and Kinzler, 1993). These
alterations provide putative markers for tumour progression.
Amongst the epigenetic alterations, aberrant expression of variants
of the CD44 gene (CD44v) is frequent and some isoforms might
have an important role in tumour progression suggesting a
complex role for CD44 in colorectal malignancy. Although contra-
dictory findings have been reported in colorectal carcinoma,
several groups have described a correlation between tumour
progression and CD44v6 expression (Wielenga et al, 1993; Finn
et al, 1994; Mulder et al, 1995). CD44v6 overexpression has
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disease (Mulder et al, 1994; Ropponen et al, 1998; Wielenga et al,
1998). We therefore decided to evaluate CD44v6 RT-PCR as a
marker to assess the metastatic potential of circulating colorectal
cancer cells in peripheral blood.
MATERIALS AND METHODS
Cell lines
HT29, SW480 and HCT8R colon carcinoma cell lines were grown
in RPMI-1640 containing L-glutamine and sodium bicarbonate
(Sigma, Saint Quentin Fallavier, France) supplemented with 10%
fetal calf serum, penicillin (100 units ml–1) and streptomycin
(0.1 mg ml–1). Cells were maintained at 37°C in 5% carbon
dioxide and passaged twice a week.
Blood samples and patients
Blood samples (5 ml) were collected in heparinized tubes and
stored at 4°C for a maximum of 2 h before treatment. For
colorectal cancer patients, blood sampling was performed immedi-
ately before the beginning of surgery. Staging was performed
according to Astler and Coller (1954). Two stage B1, three stage
B2, two stage C2 and three stage D patients were included in this
study. The mean age of the patients (four women and six men) was
64 years (range 48–81, median 66).
Blood samples collected from patients with gastrointestinal
diseases were used as controls. Twelve patients were studied: four
gastric ulcers, three colitis, one sigmoiditis, one purpura, one
Crohn’s disease, one gastritis and one diverticulosis. The mean age
of these patients (four women and eight men) was 61.4 years
(range 17–88, median 68).
RNA extraction
Total cellular RNA was extracted from cultured cells and normal
peripheral blood nucleated cells with TRIZOL reagent (Life
Technologies) according to the manufacturer’s instructions.
RT-PCR
The reverse transcription reaction and PCR amplification were
performed in a Crocodile III thermal reactor (Appligene, Illkirch,
France). Aerosol-resistant tips (CML, Nemours, France) were
used to prevent contamination.
Total RNA was heated at 72°C for 3 min, and then cooled on
ice. It was then combined with 0.5 mg of random hexamers
(Promega, Lyon, France), transcription buffer (50 mM Tris–HCl
pH 8.3, 75 mM potassium chloride (KCl), 3 mM magnesium chlo-
ride (MgCl2), 10 mM dithrothreitol (DTT), dNTPs (1 mM each),
RNAasin (50 units; Promega) and RNAaseH- M-MLV reverse
transcriptase (200 units; Promega) in a total volume of 20 ml.
Incubation was performed at 42°C for 60 min.
Amplifications were performed with 2 ml of cDNA in a total
volume of 50 ml containing 1 ´ PCR buffer (10 mM Tris–HCl
pH 9.0, 50 mM KCl, 1.5 mM MgCl2, 0.1% Triton X-100 and
0.2 mg ml–1 gelatin), 200 mM of each dNTP, 100 pmoles outer
primers, and 2.5 units Taq DNA polymerase (Life Technologies).
For reamplification with the nested primers, 0.5 ml of the first
amplification was amplified in a final volume of 50 ml with inner
primers as described above.
Cytokeratin 19 PCR were performed as previously described
(Denis et al, 1997).
For CD44 amplifications, primers were designed from the
published sequence for human CD44 gene (Screaton et al, 1992).
Their location is presented on Figure 1. The sequence of these
primers were:
RC1 – 5¢ primer: 5¢-AGCAACCCTACTGATGAT-
GACG-3¢
v6.1 – 3¢ primer: 5¢-GGAGTCTTCTCTGGGT-
GTTTGG-3¢
RC2 – 5¢ nested primer: 5¢-AGGAGGTTACATCTTTTA-
CACC-3¢
v6.2 – 3¢ nested primer: 5¢-ACCACTGTTCTTCTGGG-
TAGC-3¢
Thirty-five cycles were carried out (92°C for 30 s, 60°C for 30
s, 72°C for 60 s) followed by a 3 min final extension at 72°C.
Primers to amplify a fragment of the CD8 a-chain were
designed from the published sequence (Littman et al, 1985) using
the Genejockey™ software (Biosoft, Cambridge, UK). They were
selected on different exons of the CD8 gene (Nakayama et al,
1989) so that DNA amplified from genomic DNA would be larger
than the fragment amplified from cDNA. The sequence of these
primers were:
CD8/1 – 5¢ primer: 5¢-GCGGTTCTCGGGCAA
GAGGTT-3¢
CD8/2 – 3¢ primer: 5¢-GCGATGGTGGGCGCCG
GTGTT -3¢
CD8/3 – 5¢ nested primer: 5¢-GTCCTCACCCTGAGCGA
CTTC -3¢
CD8/4 – 3¢ nested primer: 5¢-CGTCGTGTGGGCTTCGC-
TGG -3¢.
For amplifications and nested amplifications the following
thermal profile was used: 92°C for 20 s, 62°C for 30 s, 72°C for
20 s, for 35 cycles, followed by a 3 min final extension at 72°C.
The expected size for the nested amplification was 126 bp.
Gel electrophoresis of PCR products
RT-PCR products were analysed by electrophoresis on 2% agarose
gels and visualised with ethidium bromide. A 100-bp DNA ladder
(Promega) was used as size markers.
Immunomagnetic separation
Blood samples were washed 3 times with cold phosphate-buffered
saline (PBS) and 1-ml samples were transferred to separate tubes
and analysed independently. Magnetic beads covalently coated
with monoclonal antibody BerEP4 (DYNAL, Oslo, Norway) were
then added (4 ´ 106 beads ml–1 of blood). Following incubation
performed at 4°C for 30 min, cells bound to the beads were
retrieved using a magnetic field. The beads were then washed 3
times with PBS. Total RNA was extracted from the cells immobi-
lized on the beads with TRIZOL reagent. cDNA was synthesized
and amplified as described above.
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Sensitivity
We have used a combination of reverse transcriptase and poly-
merase chain reaction (two successive amplifications) to detect
mRNA species containing exon 11 (v6) using 5¢ primers specific
for the constant region (exon 5) and 3¢ primers specific for this
variant exon (Figure 1A). We first determined the sensitivity of
this assay. Total RNA was extracted from 105 colorectal cancer
cells. Serial dilution of RNA were then performed and processed
for cDNA synthesis and amplification. A clear signal was obtained
with RNA corresponding to ten HT29 or SW480 colon carcinoma
cells, or 100 HCT8R cells (Figure 2). In all cases, the prominent
fragment amplified was approximately 150-bp long. This corre-
sponds to a transcript where no variant exon is present between the
constant domain (exon 5) and the v6 exon (exon 11). Additional
270-bp, 380-bp, 500-bp and 600-bp amplicons were also detected.
These fragments were purified from agarose gels and sequenced.
This analysis revealed that they correspond to mRNA molecules in
which, between exons 5 and 11, were inserted exon v5, exons
v4–v5, v3–v4–v5 and v2–v3–v4–v5, respectively (Figure 1B).
This pattern is in complete agreement with the variety of CD44
mRNAs described for colon cancer cell lines (van Weering et al,
1993).
RT-PCR analysis of whole blood
We then analysed normal blood samples collected in heparinized
tubes. Erythrocytes were lysed and total cellular RNA was
extracted from the nucleated cells. Reverse transcription and
amplification were performed. As shown in Figure 3, the nested
amplifications yielded similar amplified products in all the normal
samples analysed. As seen for colon cancer cell lines, different
DNA fragments corresponding to different combinations of
variant exons were amplified. These variants are expressed by
normal cells present in the blood of healthy donors. Therefore, this
amplification procedure cannot be used to detect colorectal carci-
noma cells in whole blood.
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Figure 1 (A) Schematic representation of the coding region of the human CD44 gene (dark boxes, constant exons; clear boxes, variant exons) and
localization of the primers used to amplify CD44 transcripts containing exon v6. Exon 6 or v1 (stripped box) is not expressed in humans (Screaton et al, 1993).
A first amplification was performed using oligonucleotides RC1 and v6.1 (PCR1). A nested PCR amplification was then performed with oligonucleotides RC2
and v6.2 (PCR2). (B) Schematic representation of the different CD44 splice transcripts detected in colon cancer cells (Figure 2)
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Figure 2 Sensitivity of the nested RT-PCR. Total cellular RNA was extracted from HCT8R, HT29 and SW480 colon cancer cells. Reverse transcription and
amplifications were performed as detailed in Materials and Methods from ten cells (2), 100 cells (3), 1000 cells (4), 10 000 cells (5), 100 000 cells (6) or water as
negative control (1)RT-PCR following immunomagnetic separation
In order to get rid of most normal nucleated cells, we included an
enrichment step based on the use of a specific monoclonal anti-
body coupled to magnetic beads. We used monoclonal antibody
BerEP4 which recognizes an epitope on the protein moiety of two
34-kDa and 39-kDa glycopeptides expressed at the surface of
epithelial cells in normal and malignant tissues (Momburg et al,
1987) and colorectal tumours (Latza et al, 1990). We have previ-
ously described the use of this reagent to isolate epithelial cells
from blood samples (Denis et al, 1997). RNA is extracted from the
cells immobilized on the magnetic beads. Nested RT-PCR is then
performed using oligonucleotides designed from the sequence of
the cytokeratin 19 gene. We are thus able to detect one epithelial
cell in 1 ml of whole blood (Denis et al, 1997).
In the present report, we analysed 54 samples from 22 patients:
12 patients with a gastrointestinal disease (18 samples), used as
controls, and ten patients with a colorectal cancer before they
underwent surgery (36 samples). All these samples were first
assayed for the presence of epithelial cells by cytokeratin 19 RT-
PCR. We also applied the RT-PCR amplification using CD44
oligonucleotides to cDNA synthesized from blood samples treated
with these magnetic beads.
None of the patients used as negative controls were found to
contain epithelial cells in their blood (Table 1). By contrast, we
were able to detect CD44 transcripts containing exon v6 in 9 out of
these 18 samples tested (50%).
For the colorectal cancer patients, seven samples (from one
stage B1, two stage B2 and three stage D patients) were found to
contain epithelial cells (Table 2). Six out of the seven 1-ml
samples that were cytokeratin 19-positive were CD44v6-negative.
This is most likely related to the different sensitivity of the
markers used for RT-PCR: one cell for cytokeratin 19, 10–100
cells for CD44v6. More importantly, ten samples out of the 29
samples which did not contain epithelial cells (34.5%) were found
to be CD44v6-positive. These data were analysed by c2 test. There
was no association between the results of cytokeratin 19 and
CD44v6 amplifications (P = 0.29) for colorectal cancer patients.
We have not been able to demonstrate any significant quantita-
tive or qualitative differences between amplified fragments
containing CD44v6 from patients with non-cancerous gastro-
intestinal disease and patients with colorectal cancer. The major
fragment amplified corresponded to the mRNA in which exon v6
is directly linked to the constant domain (150 bp, Figure 4A).
Larger fragments were barely detectable. Finally, there was no
statistically significant difference between the percentage of
CD44v6 PCR-positive results obtained for the gastrointestinal
diseases and the colorectal cancers (c2 test, P = 0.16).
In an attempt to identify cells of non-epithelial origin present in
the enriched preparations that express CD44v6, we performed
additional amplifications on these cDNAs. In a recent report,
Wittig et al (1999) evaluated the expression of CD44 variant
isoforms on peripheral blood leucocytes by flow cytometry.
CD44v6 was predominant detected on CD8+ cells from healthy
donors. Therefore, we performed amplifications with
oligonucleotides derived from the sequence of the CD8 a-chain.
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Figure 3 Nested RT-PCR detection of CD44 transcripts containing exon v6
in RNA extracted from whole blood. Total cellular RNA was prepared from
nucleated peripheral blood cells of six healthy volunteers (29–34). Reverse
transcription and amplifications were performed as detailed in Materials and
Methods. Negative controls were performed using water for the reverse
transcription (1), the first PCR (2) and the nested amplification (3). A positive
control was performed with RNA from HT29 colon cancer cells (4)
Table 1 RT-PCR analysis of samples from 12 patients with a
gastrointestinal disease
Samples PCR CD44v6+ PCR CD44v6–
PCR cytokeratin 19+ 0 0 0
PCR cytokeratin 19– 18 9 (50%) 9 (50%)
Table 2 RT-PCR analysis of samples from ten colorectal cancer patients
Samples PCR CD44v6+ PCR CD44v6–
PCR cytokeratin 19+ 7 1 (14.3%) 6 (85.7%)
PCR cytokeratin 19– 29 10 (34.5%) 19 (65.5%)
12 3 4 5 67 8












Figure 4 Detection of CD44 RNA transcripts containing exon v6 following
immunomagnetic separation. Blood samples from patients with a non-
cancerous gastrointestinal disease (1–4) or from patients with a colorectal
cancer (5–8) were treated with anti-epithelial cells magnetic beads. Reverse
transcription and amplifications were performed as detailed in Materials and
Methods. The cytokeratin 19 amplifications were all negative. The CD44v6
amplifications (A) and the CD8 a chain amplifications (B) are shownFigure 4 illustrates the results obtained with eight samples (four
from gastrointestinal disease patients and four from colorectal
cancer patients) that did not contain epithelial cells (PCR for
cytokeratin 19-negative). Seven of these eight samples were found
to contain CD44v6-expressing cells (panel A). Six samples were
positive for CD8 a-chain (Figure 4B). This clearly indicates that
most of the preparations obtained following immunomagnetic
separation still contain CD8+ lymphocytes. Sample 3 is negative
for CD8 a-chain, but the preparation could contain other blood
cell types, such as CD4+ or CD19+ lymphocytes, some of which
also express CD44v6 (Wittig et al, 1999).
The conclusion, therefore, is that even if most nucleated cells
normally present in blood are removed by the immunomagnetic
separation, detection of CD44 transcripts containing exon v6 using
a sensitive nested RT-PCR assay does not allow identification of
circulating epithelial cancer cells.
DISCUSSION
CD44 is a widely distributed cell surface adhesion molecule that is
involved in critical biological processes such as lymphocyte
homing and activation, cell motility, cell–matrix interaction and
the regulation of tumour cell growth and metastasis (reviewed in
Naot et al, 1997). Primary transcripts of the CD44 gene can be
alternatively spliced to produce a variety of mRNA species
(Screaton et al, 1992). The most abundant transcript corresponds
to the standard or haematopoietic form. This RNA lacks the entire
variable region, with exon 5 being linked to exon 16 (Figure 1).
Alternatively spliced variants expressed in rat tumours have been
shown to confer metastatic potential to non-metastatic carcinoma
cell lines (Günther et al, 1991), and human homologues of rat
variant mRNA sequences are expressed in human tumours (Heider
et al, 1993).
For the detection of circulating epithelial-derived tumour cells
in peripheral blood, the haematopoietic form is unsuitable because
it is the most widely expressed type of CD44 in blood and in
normal or tumoural colorectal tissue (Imazeki et al, 1996).
Conversely, in patients with non-malignant disorders of the
haematopoietic system, expression of CD44 variants in peripheral
blood leucocytes was very low (Khaldoyanidi et al, 1996).
In normal colon mucosa, CD44v6 was present and detected
on the colonic epithelium predominantly in the crypt base
(Orzechowzki et al, 1995; Gotley et al, 1996; Givehchian et al,
1998). Standard and variant CD44 transcripts were both increased
in carcinomas as compared with the corresponding normal mucosa
(Gorham et al, 1996). Each variant exon from v2 to v8–v10 was
detected in tumours for each Dukes’ stage (Gotley et al, 1996).
However, CD44v6 is the variant exon that has been most
frequently associated with metastasis. In tumour tissues the abun-
dant CD44v6 transcripts were localized exclusively in the cancer
cells (Gorham et al, 1996). Abundant CD44v6 expression could be
found in benign adenomatous polyps as well as in hepatic metas-
tases of colorectal tumours (Heider et al, 1993). Several authors
have reported that the increased expression of CD44v6 was a
marker of tumour progression in human colorectal cancer
(Wielenga et al, 1993; Mulder et al, 1995; Ropponen et al, 1998).
Others have reported discordant results without any correlation
between the expression or location of the CD44v6 protein and
clinical parameters such as tumour grade, stage or patient survival
(Gotley et al, 1996; Givehchian et al, 1998). The conclusion of
these discordant studies were based on immunohistochemical
analyses using different antibodies which might explain this
discrepancy. Anyhow, CD44v6 is overexpressed during colorectal
tumorigenesis in man and detected by immunochemistry in > 80%
of tissue specimens from benign adenomatous polyp to colonic
adenocarcinomas (Gotley et al, 1996). Expression of CD44v6 can
thus be considered as an early event in colorectal carcinogenesis
(Kim et al, 1994; Imazeki et al, 1996). Thus CD44v6 may be a
particularly useful target for identification of circulating colorectal
cancer cells.
We designed a highly sensitive nested RT-PCR assay based on
5¢ oligonucleotides located on the constant region (exon 5), and 3¢
oligonucleotides on the v6 exon (exon 10). The amplified products
were thus of limited and well-defined size. Using this amplifica-
tion method, the potential of CD44v6 expression to detect
colorectal tumour cells in peripheral blood has been evaluated. In
all mRNA preparations derived from normal blood, we identified a
similar pattern of alternatively spliced CD44 transcripts. This
nested amplification assay is more sensitive than the RT-PCR and
Southern blot hybridization presented in their preliminary report
by Wong et al (1997). A complex pattern of CD44 transcripts was
amplified, suggesting that variant mRNAs are expressed by
normal peripheral blood nucleated cells. During completion of this
manuscript, similar observation were reported for exons 8–11
(Eltahir et al, 1998).
A fraction of blood mononucleated cells of healthy donors have
been shown to express CD44v6 (Khaldoyanidi et al, 1996; Wittig
et al, 1999). Alternative splicing of CD44 isoforms in human
peripheral blood leucocytes is differentially regulated and depends
on their stage of activation (Wittig et al, 1999). The major
CD44 isoform on lymphocytes is the smallest standard molecule.
T lymphocytes, upon activation up-regulate expression of specific
CD44 variants (Koopman et al, 1993). A similar up-regulation of
CD44 splice variants can be found upon activation of B lympho-
cytes (Kryworuckho et al, 1995). CD44v6 expression is associated
with differentiation of monocytes to tissue macrophages in vivo in
inflammatory sites (Levesque et al, 1996).
To increase the specificity of the assay, immunomagnetic beads,
labelled with an epithelium-specific monoclonal antibody, were
used to isolate epithelial colorectal tumour cells from blood and
remove most of the CD44v6-expressing cells of non-epithelial
origin. Unfortunately, the combination of these two techniques,
one based on the detection of a membrane antigen by a mono-
clonal antibody, the other one based on nested RT-PCR, was still
not specific as judged by the high rate of false-positives in our
control group. We clearly demonstrated that CD8+ cells are still
present in most of the samples following immunomagnetic separa-
tion. At the moment, we cannot exclude the presence of other
subsets of blood cells in these preparations.
All cancer staging systems seek to identify clinical and patho-
logical features that can predict outcome or guide therapy.
Detection of epithelial tumour cells in blood might help in the
selection of patients at high risk for metastases in the group of
patients who are assessed presently with a good prognosis.
Detection of early blood micrometastases in some of these patients
might be used to guide therapy. We are at present investigating
whether stage B and C colorectal cancer patients with occult
potential micrometastases in their blood, detected by immunomag-
netic separation and cytokeratin 19 RT-PCR, have a significantly
decreased long-term survival or not. But there is still a need for
markers that could be used to assess the metastatic potential of
circulating cells.
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